BFPET
Alternative Names: 18-F FTPP; BFPET; BFPET (18)F-TPPLatest Information Update: 28 Apr 2019
At a glance
- Originator Harvard Medical School; Massachusetts General Hospital
- Developer FluoroPharma
- Class Imaging agents; Organophosphorus compounds
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coronary artery disease
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Coronary artery disease(Diagnosis, In volunteers) in USA (IV, Injection)
- 31 Mar 2017 Phase I development for Coronary artery disease (Diagnosis) is ongoing USA (IV)
- 31 Mar 2017 FluoroPharma has patent protection for the composition and method of use of 18-F FCPHA and 18-F FTPP technologies